803712-70-1Relevant articles and documents
Synthetic prodiginine obatoclax (GX15-070) and related analogues: Anion binding, transmembrane transport, and cytotoxicity properties
Diaz De Grenu, Borja,Hernandez, Paulina Iglesias,Espona, Margarita,Quinonero, David,Light, Mark E.,Torroba, Tomas,Perez-Tomas, Ricardo,Quesada, Roberto
, p. 14074 - 14083 (2011)
Synthetic prodiginine obatoclax shows promise as a potential anticancer drug. This compound promotes apoptosis of cancer cells, although the mechanism of action is unclear. To date, only the inhibition of BCL-2 proteins has been proposed as a mechanism of action. To gain insight into other possible modes of action, we have studied the anion-binding properties of obatoclax and related analogues in solution, in the solid state, and by means of density functional theory calculations. These compounds are well suited to interact with anions such as chloride and bicarbonate. The anion-transport properties of the compounds synthesized were assayed in model phospholipid liposomes by using a chloride-selective-electrode technique and 13C NMR spectroscopy. The results demonstrated that these compounds are efficient anion exchangers that promote chloride, bicarbonate, and nitrate transport through lipid bilayers at very low concentrations. In vitro studies on small-cell lung carcinoma cell line GLC4 showed that active ionophores are able to discharge pH gradients in living cells and the cytotoxicity of these compounds correlates well with ionophoric activity.
Novel imidazopyridine suppresses STAT3 activation by targeting SHP-1
Su, Jung-Chen,Wu, Szu-Hsien,Shiau, Chung-Wai,Chang, Chuan-Hsun
, p. 1248 - 1255 (2018/10/31)
The unregulated activation of STAT3 has been demonstrated to occur in many cancers and enhances tumour growth, migration, and invasion. Stimulation by cytokines, growth factors, and hormones triggers this activation by phosphorylating STAT3 at tyrosine 705. Novel imidazopyridine compounds were synthesized to evaluate the inhibition of STAT3 at Y705. Among the tested compounds, 16 reduced the level of phospho-STAT3, inhibited the downstream signalling cascade and subsequently attenuated the survival of hepatocellular carcinoma (HCC) cells. Further assays showed that the reduction effects of compound 16 on tyrosine 705 of STAT3 were attributed to up-regulation of protein tyrosine phosphatase SHP-1.
Synthesis and biological activity of obatoclax derivatives as novel and potent SHP-1 agonists
Su, Jung-Chen,Chen, Wei-Lin,Liu, Chun-Yu,Shiau, Chung-Wai,Chen, Kuen-Feng,Chen, Pei-Jer,Tai, Wei-Tien,Huang, Jui-Wen,Kim, Inki
, p. 127 - 133,7 (2012/12/12)
Obatoclax is a linear oligopyrrole compound which antagonizes the antiapoptotic effects of the Bcl-2 family. Herein we describe the synthesis of obatoclax derivatives by replacement of the pyrrole and indole ring of obatoclax with thiophene, furan and thiazolidinedione. The in vitro cytotoxicity of the newly synthesized compounds is evaluated against hepatocellular carcinoma cells. Pyrrole and indole substituents of obatoclax analogues exhibited potent inhibition of cell growth. Among the tested compounds, 5d and 5e were active at 6.3 and 13.2 μM against PLC5 cells. Further assays confirmed a correlation between cell death, and p-STAT3 inhibition and SHP-1 activation by these analogues.
Antimalarial activity of natural and synthetic prodiginines
Papireddy, Kancharla,Smilkstein, Martin,Kelly, Jane Xu,Shweta,Salem, Shaimaa M.,Alhamadsheh, Mamoun,Haynes, Stuart W.,Challis, Gregory L.,Reynolds, Kevin A.
, p. 5296 - 5306 (2011/10/02)
Prodiginines are a family of linear and cyclic oligopyrrole red-pigmented compounds. Herein we describe the in vitro antimalarial activity of four natural (IC50 = 1.7-8.0 nM) and three sets of synthetic prodiginines against Plasmodium falciparum. Set 1 compounds replaced the terminal nonalkylated pyrrole ring of natural prodiginines and had diminished activity (IC 50 > 2920 nM). Set 2 and set 3 prodiginines were monosubstituted or disubstituted at either the 3 or 5 position of the right-hand terminal pyrrole, respectively. Potent in vitro activity (IC50 = 0.9-16.0 nM) was observed using alkyl or aryl substituents. Metacycloprodiginine and more potent synthetic analogues were evaluated in a P. yoelii murine patent infection using oral administration. Each analogue reduced parasitemia by more than 90% after 25 (mg/kg)/day dosing and in some cases provided a cure. The most favorable profile was 92% parasite reduction at 5 (mg/kg)/day, and 100% reduction at 25 (mg/kg)/day without any evident weight loses or clinical overt toxicity.
Chemoenzymatic synthesis of prodigiosin analogues - Exploring the substrate specificity of PigC
Chawrai, Suresh R.,Williamson, Neil R.,Salmond, George P. C.,Leeper, Finian J.
, p. 1862 - 1864 (2008/12/22)
Analogues of prodigiosin, a tripyrrolic pigment produced by Serratia species with potent immunosuppressive and anticancer activities, have been produced by feeding synthetic analogues of the normal precursor MBC to mutants of Serratia sp. ATCC 39006 or to engineered strains of Escherichia coli; in this way it has been shown that the prodigiosin synthesising enzyme, PigC, has a relaxed substrate-specificity. The Royal Society of Chemistry.
Role and substrate specificity of the Streptomyces coelicolor RedH enzyme in undecylprodiginine biosynthesis
Haynes, Stuart W.,Sydor, Paulina K.,Stanley, Anna E.,Song, Lijiang,Challis, Gregory L.
, p. 1865 - 1867 (2008/12/22)
The function of RedH from Streptomyces coelicolor as an enzyme that catalyses the condensation of 4-methoxy-2,2′-bipyrrole-5-carboxaldehyde (MBC) and 2-undecylpyrrole to form the natural product undecylprodiginine has been experimentally proven, and the s
A scalable process for the synthesis of the Bcl inhibitor obatoclax
Dairi, Kenza,Yao, Yuxing,Faley, Michael,Tripathy, Sasmita,Rioux, Elise,Billot, Xavier,Rabouin, Daniel,Gonzalez, Gerson,Lavallee, Jean-Francois,Attardo, Giorgio
, p. 1051 - 1054 (2012/12/30)
Recently we created the novel indolylprodigiosin derivative 2 (obatodax) and demonstrated its ability to antagonize multiple members of the B-cell lymphoma (Bd) family of antiapoptotic proteins. The compound has shown potent anticancer activity in several animal tumor models. Obatodax is now in Phase 1b and 2 clinical trials directed against multiple hematologic and solid tumor malignancies. To support its clinical development, a new scalable synthesis was required. Obatodax has been prepared using a three-step synthesis, starting from commercially available 4-methoxy-3-pyrrolin-2-one. The reaction sequence involves a haloformylation reaction followed by a Suzuki cross-coupling reaction with an indole-2-boronic add. The synthesis is completed by an acid-mediated condensation with 2,4-dimethyl-1H-pyrrole.
METHODS FOR TREATING ARTHRITIS USING TRIHETEROCYCLIC COMPOUNDS
-
Page/Page column 103, (2008/06/13)
The present invention relates to methods for treating or preventing arthritis comprising administering a Triheterocyclic Compound. In one embodiment, the present invention relates to methods of using Triheterocyclic Compounds for treating or preventing rh
Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases
-
Page/Page column 45-46, (2010/02/14)
The present invention relates to novel Triheterocyclic Compounds, compositions comprising a Triheterocyclic Compound, and methods useful for treating or preventing cancer or a neoplastic disorder comprising administering a Triheterocyclic Compound. The compounds, compositions, and methods of the invention are also useful for inhibiting the growth of a cancer cell or neoplastic cell, treating or preventing a viral infection, or inhibiting the replication and/or infectivity of a virus.
TRIHETEROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING CANCER OR VIRAL DISEASES
-
, (2008/06/13)
The present invention relates to novel Triheterocyclic Compounds, formula (I): and pharmaceutically acceptable salts thereof, where in: Q1 is -O-, -S- or -N(R1)-; Q2 is -C(R3)- or -N-; Q3 is -C (Rsub
